Jason M. Harris
Research Subjects
Jason M. Harris has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anabel R. Miller
Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health
6 shared publications - Bruce E. Gelb
Department of Surgery, Transplant Institute, New York University Langone Health, New York, NY
6 shared publications - Eduardo D. Md Rodriguez
Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY
6 shared publications - Sergio A. Segrera
Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health
6 shared publications - Daniel J. Ceradini
Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, USA
5 shared publications - Anandhini D. Narayanan
Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health
4 shared publications
Latest Publications
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1170-e1175
Chapter 9: The Effect of Rituximab-Based Induction on Lymphocyte Subset Recovery in Vascularized Composite Allotransplantation
Vascularized composite allotransplantation (VCA) restores form and function in patients with severe disfigurement, but long-term success remains limited by acute rejection (AR). Most induction protocols emphasize T-cell depletion with antithymocyte globulin (ATG) and corticosteroids. Given the immunogenicity of skin-containing allografts and growing recognition of B-cell contributions to alloimmunity, our institution incorporated rituximab, a CD20-directed monoclonal antibody, into induction therapy. We characterized B- and T-cell reconstitution through the first episode of AR in 4 VCA recipients transplanted at a single institution, all of whom underwent induction with rituximab, ATG, and methylprednisolone, followed by maintenance therapy with tacrolimus, mycophenolate mofetil, and prednisone. Serial peripheral blood samples were analyzed by flow cytometry for absolute counts of CD3+ T cells and CD19+ B cells. All recipients demonstrated near-complete CD19+ B-cell depletion after induction. In Patients 1 to 3, CD19+ counts remained suppressed for ∼200 days; these patients subsequently experienced their first AR on postoperative day (POD) 914, 536, and 282, respectively. Patient 4 demonstrated rapid depletion and persistent suppression of CD19+, remaining rejection-free throughout follow-up. In contrast, CD3+ reconstitution was heterogeneous: Patients 1 and 2 demonstrated gradual recovery, Patient 3 had marked fluctuations, and Patient 4 exhibited persistent suppression. Rituximab-based induction produced durable B-cell depletion across all recipients, while T-cell recovery was heterogeneous and appeared temporally associated with rejection. The absence of rejection in the single recipient with persistently low CD3+ and CD19+ counts suggests that delayed global immune reconstitution may contribute to prolonged graft stability. These observations support longitudinal monitoring of lymphocytes and warrant validation in larger cohorts.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1170-e1175
Chapter 9: The Effect of Rituximab-Based Induction on Lymphocyte Subset Recovery in Vascularized Composite Allotransplantation
Vascularized composite allotransplantation (VCA) restores form and function in patients with severe disfigurement, but long-term success remains limited by acute rejection (AR). Most induction protocols emphasize T-cell depletion with antithymocyte globulin (ATG) and corticosteroids. Given the immunogenicity of skin-containing allografts and growing recognition of B-cell contributions to alloimmunity, our institution incorporated rituximab, a CD20-directed monoclonal antibody, into induction therapy. We characterized B- and T-cell reconstitution through the first episode of AR in 4 VCA recipients transplanted at a single institution, all of whom underwent induction with rituximab, ATG, and methylprednisolone, followed by maintenance therapy with tacrolimus, mycophenolate mofetil, and prednisone. Serial peripheral blood samples were analyzed by flow cytometry for absolute counts of CD3+ T cells and CD19+ B cells. All recipients demonstrated near-complete CD19+ B-cell depletion after induction. In Patients 1 to 3, CD19+ counts remained suppressed for ∼200 days; these patients subsequently experienced their first AR on postoperative day (POD) 914, 536, and 282, respectively. Patient 4 demonstrated rapid depletion and persistent suppression of CD19+, remaining rejection-free throughout follow-up. In contrast, CD3+ reconstitution was heterogeneous: Patients 1 and 2 demonstrated gradual recovery, Patient 3 had marked fluctuations, and Patient 4 exhibited persistent suppression. Rituximab-based induction produced durable B-cell depletion across all recipients, while T-cell recovery was heterogeneous and appeared temporally associated with rejection. The absence of rejection in the single recipient with persistently low CD3+ and CD19+ counts suggests that delayed global immune reconstitution may contribute to prolonged graft stability. These observations support longitudinal monitoring of lymphocytes and warrant validation in larger cohorts.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1159-e1161
Chapter 6-Teamwork in Vascularized Composite Allotransplantation: The Role of Multidisciplinary Collaboration and Rehearsal
Vascularized composite allotransplantation (VCA) is among the most technically and logistically complex procedures in reconstructive surgery. VCA requires multiple highly specialized teams to coordinate simultaneously throughout an intricate, time-sensitive operation, making effective communication, trust, and coordination essential to patient safety and clinical outcomes. These teams span numerous disciplines, including plastic surgery, anesthesiology, psychiatry, critical care, medical ethics, nursing, perioperative services, radiology, social work, and transplant immunology. A successful transplant depends on the ability of these specialties to function as a cohesive unit. At New York University, multidisciplinary planning, cadaveric rehearsals, procedural checklists, and structured debriefings are used to integrate specialties into a collaborative team before transplantation. Rehearsals allow the team to refine technical approaches, identify potential challenges, and clarify roles and expectations, while fostering trust and effective communication. The value of this approach was demonstrated during the preparation of the first combined full-face and bilateral hand transplant. Across 11 cadaveric rehearsals, Clinical Teamwork Scales improved with repeated practice, including significant gains in communication and situational awareness. These improvements were accompanied by increased operative efficiency. This experience demonstrates that a multidisciplinary VCA team is not inherently effective by virtue of its composition. Successful VCA teams are built deliberately through shared preparation and repeated practice, transforming specialized individual expertise into coordinated achievement of a common operative goal.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1159-e1161
Chapter 6-Teamwork in Vascularized Composite Allotransplantation: The Role of Multidisciplinary Collaboration and Rehearsal
Vascularized composite allotransplantation (VCA) is among the most technically and logistically complex procedures in reconstructive surgery. VCA requires multiple highly specialized teams to coordinate simultaneously throughout an intricate, time-sensitive operation, making effective communication, trust, and coordination essential to patient safety and clinical outcomes. These teams span numerous disciplines, including plastic surgery, anesthesiology, psychiatry, critical care, medical ethics, nursing, perioperative services, radiology, social work, and transplant immunology. A successful transplant depends on the ability of these specialties to function as a cohesive unit. At New York University, multidisciplinary planning, cadaveric rehearsals, procedural checklists, and structured debriefings are used to integrate specialties into a collaborative team before transplantation. Rehearsals allow the team to refine technical approaches, identify potential challenges, and clarify roles and expectations, while fostering trust and effective communication. The value of this approach was demonstrated during the preparation of the first combined full-face and bilateral hand transplant. Across 11 cadaveric rehearsals, Clinical Teamwork Scales improved with repeated practice, including significant gains in communication and situational awareness. These improvements were accompanied by increased operative efficiency. This experience demonstrates that a multidisciplinary VCA team is not inherently effective by virtue of its composition. Successful VCA teams are built deliberately through shared preparation and repeated practice, transforming specialized individual expertise into coordinated achievement of a common operative goal.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1153-e1159
Chapter 5-Belatacept for Durable Control of Recurrent Acute Rejection in Vascularized Composite Allotransplantation: A Combined Face and Bilateral Hand Transplant Patient Report
Vascularized composite allotransplantation carries a persistently high burden of acute rejection, and standardized strategies for treatment-refractory disease remain undefined. The authors report the course of a combined face and bilateral hand transplant recipient, transplanted for sequelae of an 80% total body surface area burn, who experienced 11 episodes of acute rejection over ∼4 years despite standard triple immunosuppression and sequential adjunctive therapy with sirolimus and everolimus. Eight episodes were cellular, and 3 met criteria for antibody-mediated rejection on the basis of elevated angiotensin II type 1 receptor (AT1R) antibody rather than donor-specific antibody, which remained undetectable throughout the patient’s course. After exhausting conventional adjuncts, belatacept was added to continued calcineurin-inhibitor therapy. Over the subsequent 26 months, 4 confirmed rejection episodes occurred within the first 9 months, overlapping the loading phase and everolimus withdrawal; no episode thereafter required plasmapheresis, thymoglobulin, or rituximab, and 2 later presentations were ultimately classified as inflammatory rather than confirmed rejection. Simultaneous biopsies of the hand and facial allograft components showed discordant Banff grades, and dermal sclerosis was a recurring histologic finding across the treatment course. Renal function remained stable despite continued calcineurin-inhibitor exposure, and Epstein-Barr virus DNA remained undetectable on serial surveillance despite a donor-positive, recipient-negative serostatus mismatch. This case, among the longer-reported courses of adjunctive belatacept in this population, suggests that costimulation blockade, added to ongoing calcineurin-inhibitor therapy, may reduce the severity and treatment intensity of recurrent rejection in a previously treatment-refractory vascularized composite allograft recipient.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1153-e1159
Chapter 5-Belatacept for Durable Control of Recurrent Acute Rejection in Vascularized Composite Allotransplantation: A Combined Face and Bilateral Hand Transplant Patient Report
Vascularized composite allotransplantation carries a persistently high burden of acute rejection, and standardized strategies for treatment-refractory disease remain undefined. The authors report the course of a combined face and bilateral hand transplant recipient, transplanted for sequelae of an 80% total body surface area burn, who experienced 11 episodes of acute rejection over ∼4 years despite standard triple immunosuppression and sequential adjunctive therapy with sirolimus and everolimus. Eight episodes were cellular, and 3 met criteria for antibody-mediated rejection on the basis of elevated angiotensin II type 1 receptor (AT1R) antibody rather than donor-specific antibody, which remained undetectable throughout the patient’s course. After exhausting conventional adjuncts, belatacept was added to continued calcineurin-inhibitor therapy. Over the subsequent 26 months, 4 confirmed rejection episodes occurred within the first 9 months, overlapping the loading phase and everolimus withdrawal; no episode thereafter required plasmapheresis, thymoglobulin, or rituximab, and 2 later presentations were ultimately classified as inflammatory rather than confirmed rejection. Simultaneous biopsies of the hand and facial allograft components showed discordant Banff grades, and dermal sclerosis was a recurring histologic finding across the treatment course. Renal function remained stable despite continued calcineurin-inhibitor exposure, and Epstein-Barr virus DNA remained undetectable on serial surveillance despite a donor-positive, recipient-negative serostatus mismatch. This case, among the longer-reported courses of adjunctive belatacept in this population, suggests that costimulation blockade, added to ongoing calcineurin-inhibitor therapy, may reduce the severity and treatment intensity of recurrent rejection in a previously treatment-refractory vascularized composite allograft recipient.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1148-e1151
Chapter 3-Three Decades of Vascularized Composite Allotransplantation: OPTN Registry Characteristics and Acute Rejection Outcomes in Skin-Containing Grafts
Vascularized composite allotransplantation (VCA) literature has been constrained by incomplete registry reporting, and acute rejection (AR) in skin-containing grafts remains poorly characterized despite its clinical importance. The authors performed a retrospective cohort study using OPTN VCA transplant and follow-up data sets, encompassing the complete available registry history (1998–2025) rather than restricting to the postoversight window used in prior OPTN/SRTR reports. Baseline characteristics were summarized for all 152 VCA recipients (64 uterus, 88 nonuterus), and AR burden, timing, and baseline correlates were analyzed among 87 nonuterus, skin-containing recipients using univariable Cox regression and log-rank testing. Nonuterus transplant activity extended back to 1998, well before formal OPTN oversight began in 2014, and data completeness varied substantially by variable, organ subtype, and era; several key fields, including donor age, diagnosis, race/ethnicity, and blood type, were disproportionately missing among the earliest nonuterus recipients. Among skin-containing recipients with follow-up, 56.5% experienced at least 1 AR episode, with a median time to first rejection of 25 days and frequent recurrence (median 5 episodes per rejector). Rejection incidence and timing varied by graft type, and a higher baseline calculated panel-reactive antibody (cPRA) was associated with earlier first rejection (HR=1.015, P =0.024). These findings demonstrate that the US VCA outcomes are shaped by both heterogeneous, graft-type-specific rejection burden and longstanding gaps in registry reporting. Meaningful comparison across VCA subtypes will require standardized definitions, mandatory reporting, and systematic longitudinal follow-up, particularly for rejection-related and immunologic variables.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1148-e1151
Chapter 3-Three Decades of Vascularized Composite Allotransplantation: OPTN Registry Characteristics and Acute Rejection Outcomes in Skin-Containing Grafts
Vascularized composite allotransplantation (VCA) literature has been constrained by incomplete registry reporting, and acute rejection (AR) in skin-containing grafts remains poorly characterized despite its clinical importance. The authors performed a retrospective cohort study using OPTN VCA transplant and follow-up data sets, encompassing the complete available registry history (1998–2025) rather than restricting to the postoversight window used in prior OPTN/SRTR reports. Baseline characteristics were summarized for all 152 VCA recipients (64 uterus, 88 nonuterus), and AR burden, timing, and baseline correlates were analyzed among 87 nonuterus, skin-containing recipients using univariable Cox regression and log-rank testing. Nonuterus transplant activity extended back to 1998, well before formal OPTN oversight began in 2014, and data completeness varied substantially by variable, organ subtype, and era; several key fields, including donor age, diagnosis, race/ethnicity, and blood type, were disproportionately missing among the earliest nonuterus recipients. Among skin-containing recipients with follow-up, 56.5% experienced at least 1 AR episode, with a median time to first rejection of 25 days and frequent recurrence (median 5 episodes per rejector). Rejection incidence and timing varied by graft type, and a higher baseline calculated panel-reactive antibody (cPRA) was associated with earlier first rejection (HR=1.015, P =0.024). These findings demonstrate that the US VCA outcomes are shaped by both heterogeneous, graft-type-specific rejection burden and longstanding gaps in registry reporting. Meaningful comparison across VCA subtypes will require standardized definitions, mandatory reporting, and systematic longitudinal follow-up, particularly for rejection-related and immunologic variables.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1161-e1166
Chapter 7-Long-Term Skeletal Stability in Face Transplantation: A Longitudinal CT Surface Deviation Analysis
Bone-containing facial vascularized composite allotransplantation (VCA) requires precise skeletal reconstruction to restore facial projection, occlusion, orbital support, and the face's structural framework. Virtual surgical planning (VSP) and patient-specific surgical devices facilitate donor-recipient skeletal alignment, but long-term maintenance of the planned skeletal relationships has not been well quantified. We performed a retrospective longitudinal analysis of surface deviations on computed tomography (CT) images in 3 facial VCA recipients with osseous allograft components. For each recipient, early and delayed postoperative CT scans were compared with the final VSP using PROPLAN CMF. The primary outcomes were changes in surface agreement within ±1 mm for upper skull/midface and full mandible; additional skeletal subunits were evaluated as secondary outcomes. Early imaging was obtained at a mean of 23.7 days post-transplantation (range: 2–52 d), and delayed imaging at a mean of 3.12 years (range: 2.02–5.27 y). The mean upper skull/midface agreement was 86.0% at early and 83.0% at delayed follow-up, corresponding to a mean change of −3.0 percentage points (range: −7 to −1). The mean mandibular agreement increased from 50.0% to 57.7%, a mean change of +7.7 percentage points (range: −1 to +13). Secondary regional analyses demonstrated greater heterogeneity among individual skeletal subunits. These findings demonstrate sustained longitudinal concordance between postoperative skeletal position and the original VSP over multiyear follow-up. VSP provides both a reproducible framework for precise osseous reconstruction and a durable reference for longitudinal assessment of skeletal outcomes after facial VCA. Standardized regions of interest and serial imaging protocols will be important for future comparisons across recipients and centers.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1161-e1166
Chapter 7-Long-Term Skeletal Stability in Face Transplantation: A Longitudinal CT Surface Deviation Analysis
Bone-containing facial vascularized composite allotransplantation (VCA) requires precise skeletal reconstruction to restore facial projection, occlusion, orbital support, and the face's structural framework. Virtual surgical planning (VSP) and patient-specific surgical devices facilitate donor-recipient skeletal alignment, but long-term maintenance of the planned skeletal relationships has not been well quantified. We performed a retrospective longitudinal analysis of surface deviations on computed tomography (CT) images in 3 facial VCA recipients with osseous allograft components. For each recipient, early and delayed postoperative CT scans were compared with the final VSP using PROPLAN CMF. The primary outcomes were changes in surface agreement within ±1 mm for upper skull/midface and full mandible; additional skeletal subunits were evaluated as secondary outcomes. Early imaging was obtained at a mean of 23.7 days post-transplantation (range: 2–52 d), and delayed imaging at a mean of 3.12 years (range: 2.02–5.27 y). The mean upper skull/midface agreement was 86.0% at early and 83.0% at delayed follow-up, corresponding to a mean change of −3.0 percentage points (range: −7 to −1). The mean mandibular agreement increased from 50.0% to 57.7%, a mean change of +7.7 percentage points (range: −1 to +13). Secondary regional analyses demonstrated greater heterogeneity among individual skeletal subunits. These findings demonstrate sustained longitudinal concordance between postoperative skeletal position and the original VSP over multiyear follow-up. VSP provides both a reproducible framework for precise osseous reconstruction and a durable reference for longitudinal assessment of skeletal outcomes after facial VCA. Standardized regions of interest and serial imaging protocols will be important for future comparisons across recipients and centers.
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1166-e1170
Chapter 8-Standardizing Postoperative Outcome Assessment After Face Transplantation: A Proposed Core Assessment Framework
Outcome assessment after face transplantation remains heterogeneous, limiting comparison of recovery, patient benefit, and treatment burden across programs. We sought to define a face-specific core outcome set for longitudinal postoperative assessment, informed by the NYU Langone experience and its published outcome literature. We performed a methodological inventory of postoperative assessments used across 4 NYU Langone face transplant recipients treated between 2015 and 2023 and reviewed face-relevant peer-reviewed publications available through September 2026. Recipient-level outcome values were not reanalyzed. Measures were prioritized for clinical relevance, repeatability, and suitability for longitudinal comparison. Twenty-three relevant publications from the NYU program informed the framework. The proposed core outcome set comprises 6 domains: (1) allograft integrity and surgical outcomes; (2) rejection, immunologic surveillance, and immunosuppression-related morbidity; (3) facial sensory and motor recovery; (4) speech, swallowing, and oral function; (5) structural and region-specific facial outcomes; and (6) patient-reported outcomes, rehabilitation, and treatment burden. This face-specific framework provides a clinically focused minimum data set for longitudinal outcome assessment after face transplantation. Consistent use may improve patient tracking and facilitate more meaningful comparison across programs, while prospective multicenter implementation will be necessary to refine and validate the proposed core set.
- 23 September 2026
- Published by Wolters Kluwer Health in Journal of Craniofacial Surgery
- Vol. 37 (10) , e1166-e1170
Chapter 8-Standardizing Postoperative Outcome Assessment After Face Transplantation: A Proposed Core Assessment Framework
Outcome assessment after face transplantation remains heterogeneous, limiting comparison of recovery, patient benefit, and treatment burden across programs. We sought to define a face-specific core outcome set for longitudinal postoperative assessment, informed by the NYU Langone experience and its published outcome literature. We performed a methodological inventory of postoperative assessments used across 4 NYU Langone face transplant recipients treated between 2015 and 2023 and reviewed face-relevant peer-reviewed publications available through September 2026. Recipient-level outcome values were not reanalyzed. Measures were prioritized for clinical relevance, repeatability, and suitability for longitudinal comparison. Twenty-three relevant publications from the NYU program informed the framework. The proposed core outcome set comprises 6 domains: (1) allograft integrity and surgical outcomes; (2) rejection, immunologic surveillance, and immunosuppression-related morbidity; (3) facial sensory and motor recovery; (4) speech, swallowing, and oral function; (5) structural and region-specific facial outcomes; and (6) patient-reported outcomes, rehabilitation, and treatment burden. This face-specific framework provides a clinically focused minimum data set for longitudinal outcome assessment after face transplantation. Consistent use may improve patient tracking and facilitate more meaningful comparison across programs, while prospective multicenter implementation will be necessary to refine and validate the proposed core set.